1-11 of 11
Mark J. Levis
Close
Sort by
Journal Articles

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2 -mutated myeloid malignancies

Clinical Trials & Observations
Amir T. Fathi, Haesook T. Kim, Robert J. Soiffer, Mark J. Levis, Shuli Li, Annette S. Kim, Alice S. Mims, Zachariah DeFilipp, Areej El-Jawahri, Steven L. McAfee, Andrew M. Brunner, Rupa Narayan, Laura W. Knight, Devon Kelley, AJ S. Bottoms, Lindsey H. Perry, Jonathan L. Wahl, Jennifer Brock, Elayne Breton, Vincent T. Ho, Yi-Bin Chen
Journal: Blood Advances
Blood Adv (2022) 6 (22): 5857–5865.
https://doi.org/10.1182/bloodadvances.2022008632
Published: 2022
Includes: Supplemental data
Journal Articles

Molecular profile of FLT3 -mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

Clinical Trials & Observations
Catherine C. Smith, Mark J. Levis, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2144–2155.
https://doi.org/10.1182/bloodadvances.2021006489
Published: 2022
Includes: Supplemental data
Journal Articles

Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis

David J. Young, Bao Nguyen, Ruiqi Zhu, Jaesung Seo, Li Li, Mark J. Levis, Keith W. Pratz, Amy S. Duffield, Donald Small
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2285–2293.
https://doi.org/10.1182/bloodadvances.2020002876
Published: 2021
Includes: Supplemental data
Journal Articles

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

Clinical Trials & Observations
Cheryl A. C. Peretz, Lisa H. F. McGary, Tanya Kumar, Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, Mark J. Levis, Alexander Perl, Benjamin J. Huang, Catherine C. Smith
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1437–1441.
https://doi.org/10.1182/bloodadvances.2020003398
Published: 2021
Includes: Supplemental data
Journal Articles

Allogeneic transplantation for Ph + acute lymphoblastic leukemia with posttransplantation cyclophosphamide

Clinical Trials & Observations
Jonathan A. Webster, Leo Luznik, Hua-Ling Tsai, Philip H. Imus, Amy E. DeZern, Keith W. Pratz, Mark J. Levis, Ivana Gojo, Margaret M. Showel, Gabrielle Prince, Javier Bolaños-Meade, Lukasz P. Gondek, Gabriel Ghiaur, W. Brian Dalton, Tania Jain, Ephraim J. Fuchs, Douglas E. Gladstone, Christian B. Gocke, Syed Abbas Ali, Carol Ann Huff, Ivan M. Borrello, Lode Swinnen, Nina Wagner-Johnston, Richard F. Ambinder, Richard J. Jones, B. Douglas Smith
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5078–5088.
https://doi.org/10.1182/bloodadvances.2020002945
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

Clinical Trials & Observations
Catherine C. Smith, Mark J. Levis, Olga Frankfurt, John M. Pagel, Gail J. Roboz, Richard M. Stone, Eunice S. Wang, Paul L. Severson, Brian L. West, Mai H. Le, Sabine Kayser, Bao Lam, Henry H. Hsu, Chao Zhang, Gideon Bollag, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1711–1721.
https://doi.org/10.1182/bloodadvances.2020001449
Published: 2020
Includes: Supplemental data
Journal Articles

The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing

W. Brian Dalton, Eric Helmenstine, Lisa Pieterse, Bing Li, Christopher D. Gocke, Joshua Donaldson, Zhijian Xiao, Lukasz P. Gondek, Gabriel Ghiaur, Ivana Gojo, B. Douglas Smith, Mark J. Levis, Amy E. DeZern
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1192–1196.
https://doi.org/10.1182/bloodadvances.2019001127
Published: 2020
Includes: Supplemental data
Journal Articles

Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors

Yu-Ting Chang, Daniela Hernandez, Salvador Alonso, Minling Gao, Meng Su, Gabriel Ghiaur, Mark J. Levis, Richard J. Jones
Journal: Blood Advances
Blood Adv (2019) 3 (6): 908–916.
https://doi.org/10.1182/bloodadvances.2018022921
Published: 2019
Includes: Supplemental data
Journal Articles

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3 -ITD mutations

Clinical Trials & Observations
Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller
Journal: Blood Advances
Blood Adv (2018) 2 (8): 825–831.
https://doi.org/10.1182/bloodadvances.2018015925
Published: 2018
Includes: Supplemental data
Journal Articles

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3 -mutated acute myeloid leukemia: CALGB 11001

Clinical Trials & Observations
Geoffrey L. Uy, Sumithra J. Mandrekar, Kristina Laumann, Guido Marcucci, Weiqiang Zhao, Mark J. Levis, Heidi D. Klepin, Maria R. Baer, Bayard L. Powell, Peter Westervelt, Daniel J. DeAngelo, Wendy Stock, Ben Sanford, William G. Blum, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2017) 1 (5): 331–340.
https://doi.org/10.1182/bloodadvances.2016003053
Published: 2017
Journal Articles

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide

Clinical Trials & Observations
Yvette L. Kasamon, Richard F. Ambinder, Ephraim J. Fuchs, Marianna Zahurak, Gary L. Rosner, Javier Bolaños-Meade, Mark J. Levis, Douglas E. Gladstone, Carol Ann Huff, Lode J. Swinnen, William H. Matsui, Ivan Borrello, Robert A. Brodsky, Richard J. Jones, Leo Luznik
Journal: Blood Advances
Blood Adv (2017) 1 (4): 288–292.
https://doi.org/10.1182/bloodadvances.2016002766
Published: 2017
Includes: Supplemental data